Big Pharma and contract development and manufacturing organizations are making large capital expenditures to build infrastructure supporting the wildly popular medications.
Ongoing investments in its Fishers, Indiana and Latina, Italy sites are expanding capacity for high-value products, while the company pivots away from other categories.
Lilly is struggling to find the talent required for these capital expenditure projects, says Steve Marr, head of the drugmaker’s global facilities delivery parenteral.
Home to pharma giants Roche and Novartis, the Swiss city along the Rhine River is attracting biotech companies of all sizes that are driving life sciences innovation.
With the launch of the Wegovy pill in the U.S., the drugmaker is adding manufacturing capacity to its Athlone, Ireland site to support current and future GLP-1 treatments.
Chris Chen, CEO of WuXi Biologics, discusses his organization’s approach to ensuring consistent quality, reliability, and speed of biologics development and manufacturing.
Overall, the company’s specialty CDMO business grew in the low-double digits during the first quarter of fiscal 2026, with expectations of mid-teens growth this year.
The company is selling contract development and manufacturing organization sites in Tennessee, Maryland, and the UK, as well as a cell solutions site in California.
Of about $600 billion in domestic investments announced in 2025, only $60 billion worth of estimated capital expenditures have specific amounts and locations, finds CBRE.
Since SK bioscience acquired a 60% stake in the CDMO, the company has undertaken a “full-scale drive” to expand its business in vaccines and biopharmaceuticals.
The CDMO’s “conservative” guidance is due to limited visibility around a pending customer confirmation for a large contract that could impact sales growth this year.
Despite the legal setback for President Trump’s country-specific tariffs, he retains the authority to impose Section 232 tariffs on pharmaceuticals imported to the U.S.
To counter the Chinese government’s investment, the U.S. must make a coordinated effort to grow biomanufacturing base, argues a bipartisan commission created by Congress.
The CDMO has strengthened its oral solid dose and antibody-drug conjugate capabilities as drugmakers diversify away from China and expand onshore production.
Organic revenue for the company’s manufacturing solutions decreased 2.1%, driven by lower revenue in its contract development and manufacturing organization segment.
As artificial intelligence tools proliferate, the real challenge is not generating ideas but turning them into chemically feasible and manufacturable paths.
The pharma giant has added to its inventory of orforglipron in anticipation of a favorable regulatory decision by the U.S. Food and Drug Administration.
Aiming to be Europe’s top life sciences economy by 2030, Britain must create a better business environment, argued panelists at Fujifilm’s grand opening in Teesside.
With 17 facilities in 10 countries, geopolitical uncertainty last year weighed on the Swedish-headquartered contract development and manufacturing organization.
Production is highly concentrated globally making lower- and middle-income regions vulnerable to supply shocks, regulatory bottlenecks, and slow pandemic response.
Industrializing the manufacturing of these complex therapies is critical to ensure scalability and commercial viability, says the Alliance for Regenerative Medicine.
2025 was a strong year for drugs approved by the agency with record-high outsourcing penetration. Lonza, Thermo Fisher, and Catalent remain the leaders.
Investments in its network include the company’s CDMO business in the Toronto area, where it is building a new GMP biologics facility slated for completion in 2026.
The agency will select new pharma manufacturing facilities for the pilot aimed at reducing inspection-related delays and creating a more predictable regulatory pathway.
It is the largest increase of the four major industries tracked by commercial real estate firm Newmark, which analysts contend is the start of a super-cycle for the sector.